Slingshot members are tracking this event:

Eli Lilly's (LLY) LIBRETTO-001 Phase 1/2 trial of Selpercatinib (LOXO-292) shows a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Clinical Data As of the data cut-off date of June 17, 2019, median duration of response (DOR) was 20.3 months (95% CI: 13.8-24.0) and median progression-free survival (PFS) was 18.4 months (95% CI: 12.9-24.9). Since the majority of patients remain in response or progression-free as of the data cut-off date, these medians will continue to mature over time. In a safety analysis of all 531 patients enrolled to LIBRETTO-001, selpercatinib was well-tolerated, with only 9 patients (1.7%) discontinuing therapy due to treatment-related toxicity.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 09, 2019
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nsclc, Selpercatinib, Loxo-292, Libretto-001